Furthermore, upregulation of PRPF8 correlates with poor prognosis in clinical liver cancer patients, acting as a tumor promoter by regulating the PI3K/Akt pathway in hepatic stellate cells and HCC cells, thereby enhancing liver cancer cell viability and metastatic potential. The gene discussed is AKT1; the disease is hepatocellular carcinoma.